Kirby McInerney LLP is investigating Pathward Financial for possible securities fraud following the company's report of a sharp increase in credit loss provisions and nonperforming loans, linked to a suspected sophisticated fraud in a working capital loan and issues in renewable energy projects. Pathward also lowered its 2026 earnings guidance, causing its stock to drop over 6%. The investigation is ongoing, with no lawsuit filed yet, and investors who purchased Pathward securities are encouraged to contact the law firm for more information.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Audiera (BEAT) fell sharply by 24.29%, breaking below the $3 support level to a low of $2.4 before slightly recovering to around $2.76. The drop followed increased selling pressure with significant outflows in both futures and spot markets, indicatin...
